Upon joining the study, you will be required to provide a signed written informed consent or e-consent, depending on the study group you are assigned to.

You must have been diagnosed with type 2 diabetes mellitus for at least one year and have been treated with a basal insulin for at least three months prior to joining the study.

An initial assessment will be conducted to ensure your daily basal insulin dose has been stable for at least one month before the study begins.

Your mental and physical status will be evaluated to confirm your ability to perform daily activities, including administering injectable insulin and measuring blood sugar levels.

You will be using Toujeo 300 units/ml SoloStar, a solution for injection in a pre-filled pen, administered via subcutaneous injection.

The dosage and frequency of the insulin administration will be determined by the study protocol and your healthcare provider.

You will be required to use a tablet or smartphone with Bluetooth functionality and have access to an internet connection for remote data entry.

For part B of the study, video conferencing may be necessary to facilitate data collection and communication.

If you are part of Part A of the study, you must be willing and able to permit home visits for data collection and monitoring purposes.

The study is expected to continue until August 21, 2024, with regular assessments and data collection throughout this period.

Your participation will involve adherence to the study drug receipt, accountability, and return processes and procedures.

Upon completion of the study, your data will be analyzed to assess the potential benefits of the decentralized clinical trial approach.

The study aims to evaluate participant recruitment, retention, diversity, site and participant satisfaction, and cost-effectiveness.